Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$369.56 USD

369.56
1,589,555

+9.83 (2.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $369.45 -0.11 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.

    Accuray's Radixact Now Used by Boise Summit Cancer Center

    Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.

      Globus Medical's Robotic Guidance System Gets FDA Approval

      Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.

        Cardiovascular Systems Unveils Favorable LIBERTY 360 Data

        LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.

          Anika (ANIK) Grows in Orthopedic Medicines on Positive Data

          Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.

            STERIS (STE) Banks on Organic Growth, Competition Intense

            STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.

              Model N (MODN) Q3 Loss Narrower than Expected, Revenues Miss

              Model N (MODN) reported narrower-than-expected loss in the third quarter driven by better customer acquisition.

                Is a Surprise in Store for Penumbra (PEN) in Q2 Earnings?

                Penumbra's (PEN) escalating costs and expenses may keep margins under pressure in the yet-to-be-reported second quarter.

                  Mark Vickery headshot

                  Top Stock Reports for Procter & Gamble, Altria & Bristol-Myers

                  Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Altria (MO) and Bristol-Myers (BMY).

                    The Zacks Analyst Blog Highlights: McDonald's, 3M, Stryker, Goldman Sachs and Kinder Morgan

                    The Zacks Analyst Blog Highlights: McDonald???s, 3M, Stryker, Goldman Sachs and Kinder Morgan

                      Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More

                      The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.

                        Why Earnings Season Could Be Great for Stryker Corporation (SYK)

                        Stryker Corporation (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

                          Top Stock Reports for McDonald's, 3M & Stryker

                          Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), 3M (MMM), and Stryker (SYK).

                            Ecolab (ECL) to Report Q2 Earnings: Will It Pull a Surprise?

                            Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Ecolab's (ECL) growth in the second quarter.

                              Can Cerner (CERN) Deliver a Beat this Earnings Season?

                              We believe Cerner's (CERN) strong sales performance, solid portfolio and strategic initiatives have positioned it for stellar growth.

                                Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?

                                The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.

                                  Can Illumina (ILMN) Spring a Surprise this Earnings Season?

                                  Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.

                                    Will Stryker (SYK) Deliver a Beat this Earnings Season?

                                    The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.

                                      Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?

                                      Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.

                                        McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?

                                        McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.

                                          IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?

                                          IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.

                                            What's in Store for Express Scripts (ESRX) in Q2 Earnings?

                                            Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.

                                              Baxter International (BAX) Q2 Earnings: What's in Store?

                                              Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.

                                                Varian Medical (VAR) Q3 Earnings: Is a Surprise in Store?

                                                Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.

                                                  Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?

                                                  Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.